PUBLIC COMPANY
save$ALECAlector, Inc.
$ALECSouth San Francisco, CA, USupdated 2mo ago
Alector refers to more than one person in classical mythology and history:Alector, son of Magnes and Meliboea, eponyms of Magnesia and the town of Meliboea respectively.
Alector, the Boeotian father of Leitus. Homer calls him "Alectryon", and Diodorus "Electryon", naming him among the sons of Itonus. According to Tzetzes, Alector was also the father of Clonius, Arcesilaus and Prothoenor by different mothers: he is said to have fathered Leitus with Polybule, Arcesilaus with Cleobule, Prothoenor with Arteis, and Clonius with Acteis.
Alector, an Elean prince as the son of King Epeius, and brother read more
…
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
- phase3A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
- phase3Continuation Study for Latozinemab
- phase2A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
- phase2A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
- phase2A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 16, 26SELLWong-Sarad Grace· Principal Accounting Officer−$5K↗
🐶 Hiring Signal
News
- GSK walks away from Alector pact as immuno-neurology bet fizzlesAfter two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it signed with Alector for neurodegenerative disease treatments. GSK’s e…endpoints · 2mo ago
- Avalyn's upsized IPO; Alector ends another study in GSK partnership🔔 Avalyn Pharma’s $300M IPO: The Boston, MA-based biotech is selling over 16.5 million shares at $18 apiece. The company is set to start trading as {$AVLN} on the Nasdaq Thursday ...endpoints · 5mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that